BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 26230522)

  • 1. Streptococcus pneumoniae antibody titres in patients with primary antibody deficiency receiving intravenous immunoglobulin (IVIG) compared to subcutaneous immunoglobulin (SCIG).
    Knutsen AP; Leiva LE; Caruthers C; Rodrigues J; Sorensen RU
    Clin Exp Immunol; 2015 Oct; 182(1):51-6. PubMed ID: 26230522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of Streptococcus pneumoniae serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment.
    Simão-Gurge RM; Costa-Carvalho BT; Nobre FA; Gonzalez IG; de Moraes-Pinto MI
    Allergol Immunopathol (Madr); 2017; 45(1):55-62. PubMed ID: 27480789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
    Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
    Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.
    Niebur HB; Duff CM; Shear GF; Nguyen D; Alberdi TK; Dorsey MJ; Sleasman JW
    Clin Exp Immunol; 2015 Sep; 181(3):441-50. PubMed ID: 25761372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.
    Bezrodnik L; Gómez Raccio A; Belardinelli G; Regairaz L; Díaz Ballve D; Seminario G; Moreira I; Riganti C; Cantisano C; Díaz H; Di Giovanni D
    J Clin Immunol; 2013 Oct; 33(7):1216-22. PubMed ID: 23846854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
    Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
    Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push.
    Shapiro R
    Clin Exp Immunol; 2013 Aug; 173(2):365-71. PubMed ID: 23607310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin.
    Milota T; Bloomfield M; Kralickova P; Jilek D; Novak V; Litzman J; Posova H; Mrazova L; Poloniova J; Prucha M; Rozsival P; Rauschova V; Philipp G; Sediva A
    Clin Ther; 2019 Nov; 41(11):2231-2238. PubMed ID: 31564514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional antibodies to Haemophilus influenzae type B, Neisseria meningitidis, and Streptococcus pneumoniae contained in intravenous immunoglobulin products.
    Lee S; Kim HW; Kim KH
    Transfusion; 2017 Jan; 57(1):157-165. PubMed ID: 27774610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.
    Visentin A; Molinari MC; Pravato S; Cellini A; Angotzi F; Cavaretta CA; Ruocco V; Imbergamo S; Piazza F; Proietti G; Mauro FR; Trentin L
    Curr Oncol; 2022 Dec; 30(1):274-283. PubMed ID: 36661671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.
    Gardulf A; Nicolay U; Asensio O; Bernatowska E; Böck A; Carvalho BC; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Pons J; Niehues T; Schmidt S; Schulze I; Borte M
    J Clin Immunol; 2006 Mar; 26(2):177-85. PubMed ID: 16758340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous and subcutaneous immunoglobulin G replacement therapy.
    Bonilla FA
    Allergy Asthma Proc; 2016 Nov; 37(6):426-431. PubMed ID: 27931296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.
    Abolhassani H; Sadaghiani MS; Aghamohammadi A; Ochs HD; Rezaei N
    J Clin Immunol; 2012 Dec; 32(6):1180-92. PubMed ID: 22730009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose.
    Berger M
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):532-8. PubMed ID: 21971330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
    Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
    Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
    Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
    J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of pneumococcal infection in a patient with normal immunoglobulin levels but impaired polysaccharide antibody production.
    Cohn JA; Skorpinski E; Cohn JR
    Ann Allergy Asthma Immunol; 2006 Nov; 97(5):603-5. PubMed ID: 17165266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
    Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
    J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
    Berger M; Rojavin M; Kiessling P; Zenker O
    Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.